Category Archives: Press Releases

April 11, 2019 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) reported its financial results for the three and twelve months ended December 31, 2018. All figures are reported in Canadian dollars ($), unless otherwise indicated. Delivra’s financial statements are prepared in accordance with International Financial Reporting Standards.

Highlights for Fiscal 2018:

  • Record sales of $5,052,715 representing 12% sales growth over 2017;
  • A robust gross margin of 71% for the year, in line with historical percentages;
  • Successfully launched two new LivReliefTM products during the year, LivReliefTM Extra Strength Chronic Angry Pain Relief Cream and LivReliefTM Sports & Active Pain Relief Cream;
  • Re-branded and re-packaged the LivReliefTM family of products during the year, with new impactful graphics and colours;
  • Increased the number of retail locations currently selling LivReliefTM products from 5,200 stores at the beginning of the year to over 6,000 retail locations as of today;
  • Developed a revolutionary, proprietary topical cream base therapeutic, DelivraTMN, for molecules of cannabis, cannabis-like and opioids, for a safer more targeted and consistent delivery to patients afflicted with chronic pain and anxiety;
  • Positive results received on the ability to treat pain directly with a topical version of AdvilTM (ibuprofen). Testing for effects of joint pain and inflammation, topical Delivra-ibuprofen formulation offers longer-term pain and swelling reduction compared to oral ibuprofen;
  • Signed a joint venture agreement with Intervivo Solutions for a ready to market sleep and anti-anxiety topical therapeutic cream for the animal health industry. Our expertise in formulation using our innovative delivery system platform combined with Intervivo’s success in demonstrating pharmacokinetic, safety and efficacy data in clinically relevant canine and feline models provides a unique platform for rapid development of transdermal commercial products for the veterinary market;
  • Founder and CEO, Dr. Joseph Gabriele, received the Ernst & Young Entrepreneur of the Year 2018 Ontario award in the Health Care category; and
  • Announced on March 4, 2019, that Delivra entered into a definitive arrangement agreement with Harvest One Cannabis Inc. (“Harvest One”), pursuant to which Harvest One will acquire all of the issued and outstanding common shares of Delivra. Under the terms of the agreement, shareholders of Delivra will receive 0.595 common shares of Harvest One for each Delivra share. The Transaction is subject to, among other things, the approval of the Ontario Superior Court of Justice and requires the approval of two-thirds of the votes cast by Delivra shareholders at a special meeting expected to be convened by Delivra in May, receipt of required regulatory approvals and other customary conditions of closing. Approval of shareholders of Harvest One is not required. Additional details of the Transaction will be provided to Delivra Shareholders in an information circular expected to be mailed in April. It is currently anticipated that, subject to receipt of all regulatory, court, shareholder and other approvals, the Transaction will be completed in the second quarter of 2019.
March 4, 2019 – Toronto, Ontario – Harvest One Cannabis Inc. (TSXV: HVT, OTCQX: HRVOF – “Harvest One”) and Delivra Corp. (TSXV: DVA – “Delivra”) are pleased to announce today that they have entered into a definitive arrangement agreement (the “Arrangement Agreement”) pursuant to which Harvest One will acquire all of the issued and outstanding common shares of Delivra (the “Delivra Shares”) (the “Transaction”). Under the terms of the Arrangement Agreement, shareholders of Delivra (“Delivra Shareholders”) will receive 0.595 common shares of Harvest One (the “Harvest One Shares”) for each Delivra Share (the “Exchange Ratio”).

February 6, 2019 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) today announced the publication of positive data from a laboratory and clinical study demonstrating the stability, safety and efficacy to treat diabetic wounds, using Delivra’s platform technology, to deliver a topical version of the prescription drug, doxycycline. These results were published in the respected peer-reviewed scientific journal, Wounds Research. This article may be found at the following link: https://www.ncbi.nlm.nih.gov/pubmed/30664497.
January 8, 2019 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) today announced the publication of positive data from a clinical study demonstrating the safety and efficacy to treat chronic venous insufficiency of lower limbs, using the LivReliefTM Varicose Vein Cream over-the-counter product. These results were published in the respected peer-reviewed scientific journal, PLOS ONE. This article may be found at the following link: https://doi.org/10.1371/journal.pone.0208954.

December 11, 2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) today announced the publication of positive data from a pre-clinical study demonstrating the safety and efficacy to treat pain directly with a topical version of AdvilTM (ibuprofen) and CelebrexTM (celecoxib). Testing for effects on joint pain and inflammation; topical Delivra-ibuprofen and Delivra-celecoxib formulations offer sustained long-term pain and swelling reduction, compared to oral equivalents. These results were published in the respected peer-reviewed scientific journal, Journal of Pain Research, under the title, “Penetration and efficacy of transdermal NSAIDs in a model of acute joint inflammation”. The article may be found at the following link:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239099/?report=reader

In pre-clinical testing, undertaken by an independent third-party research organization, the Delivra-ibuprofen and Delivra-celecoxib formulations provided sustained pain reduction. In the study, both Delivra formulations were tested in an acute dog model of arthritis where the formulation performed equally or better for swelling and pain reduction compared its oral equivalent and test controls. This exemplifies Delivra’s technology, with its multi-laminar system, is capable of gradually releasing the active ingredient to the area of need. This transdermal, designed “slow release” is a valuable and highly advantageous characteristic of the topical Delivra-ibuprofen and Delivra-celecoxib creams and may offer significant advantages over oral medication. These formulations will provide better localization of the drug at the site of need, yielding quicker and longer lasting relief.

“This impressive data further validates Delivra’s platform technology by outperforming oral delivery and offering patients an effective, safe and convenient cream for pain management. Our robust pharmaceutical pipeline of high-value innovative products, including Delivra-ibuprofen and Delivra-celecoxib formulations, provide an array of unique commercialization opportunities. As such, we will continue to pursue out-licensing opportunities for major global markets to unlock the value of our portfolio,” said Dr. Joseph Gabriele, CEO of Delivra.

For these two formulations, the Company has two PCT patent pending applications.

ABOUT DELIVRA CORP.

Delivra Corp. is a specialty biotechnology company having a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules through the skin, in a targeted manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and sports performance. LivReliefTM products are available in over 6,000 retail locations, including pharmacies, grocery chains, and independent health food stores across Canada, including, but not limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall, Pharmasave, London Drugs, and on-line at www.livrelief.com. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending, proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Hamilton, Ontario and has a research and development laboratory in Charlottetown, PEI.

Further information on Delivra can be found at www.delivracorp.com and www.livrelief.com.

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute “forward-looking statements”, which are not comprised of historical facts. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “intends”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”, and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the Company’s revenues and financial performance; the Company’s drug research and development plans; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Delivra to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management’s expectations. In formulating the forward-looking statements contained herein, management has assumed that business and economic conditions affecting Delivra will continue substantially in the ordinary course and will be favourable to Delivra; that the Company will continue to complete orders with existing customers and control product pricing and expenses that clinical testing results will justify commercialization of the Company’s drug candidates; that Delivra will be able to obtain all requisite regulatory approvals to commercialize its drug candidates, that such approvals will be received on a timely basis, and that Delivra will be able to find suitable partners for development and commercialization of its products and intellectual property on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect. Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: the ability of the Company to maintain existing product sales with current customers at existing product pricing and expenses; uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the ability of the Company to generate sales and profits; the Company’s ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Delivra’s public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Delivra disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Dr. Joseph Gabriele

Chief Executive Officer

info@delivracorp.com

905-561-5014

November 19, 2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) reported its financial results for the three and nine months ended September 30, 2018. All figures are reported in Canadian dollars ($), unless otherwise indicated. Delivra’s financial statements are prepared in accordance with International Financial Reporting Standards.
October 30, 2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”), a science and biotechnology company, today announced that its Founder and CEO, Dr. Joseph Gabriele, is the recipient of the Ernst & Young Entrepreneur Of The Year 2018 Ontario award in the Health Care category.
October 15, 2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”), a scientific and biotechnology company, today announced that it has issued an aggregate of 550,000 incentive stock options (the “Options”) each exercisable into one common share in the capital of the Company, to eligible participants under the Company’s incentive stock option plan (the “Plan”). The Options are exercisable at $0.36 per share for a period of five years from the date of grant, expiring on October 15, 2023. Of the Options granted, 500,000 vest immediately and 50,000 vest 50% on the first anniversary of the grant date and 50% on the second anniversary of the grant date. The options have been granted under and are governed by the terms of the Plan.
October 1, 2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”), a scientific and biotechnology company, today announced that it has recently received inquiries from a number of interested parties in relation to the Company’s proprietary transdermal delivery system platform, including its proprietary applications for the cannabis and pharma industries.

As a result of these inquiries, the Company has engaged Canaccord Genuity Corp. to act as exclusive financial advisor to identify, review, analyze and explore the range of strategic and other opportunities available to the Company within the cannabis and pharma industries. There can be no assurance that the Company will enter into any transaction, that there will be any change in the operation or ownership of the Company, or that the Company will take any other corporate action as a result of the review.

August 27, 2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) today announces the appointment of Pascal Attard as the Company’s Chief Financial Officer.

Mr. Attard has been with the Company since June 2015. For the past two years, Mr. Attard served as the Company’s Vice-President, Finance and prior to that, was the Company’s Controller. Prior to joining Delivra, Mr. Attard was Controller, Red Tiger Mining Inc. and Manager, McGovern Hurley LLP, a mid-market accounting firm where he received his CPA designation in 2009.